Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: A meta-analysisDe Vries, F. M., Kolthof, J., Postma, M. J., Denig, P. & Hak, E., 5-Nov-2014, In : PLoS ONE. 9, 11, 8 p., e111247.
Research output: Contribution to journal › Article › Academic › peer-review
Aims: To estimate the efficacy of standard and intensive statin treatment in the secondary prevention of major cardiovascular and cerebrovascular events in diabetes patients.
Methods: A systematic search was conducted in Medline over the years 1990 to September 2013. Randomized, double-blind, clinical trials comparing a standard-dose statin with placebo or a standard-dose statin with an intensive-dose statin for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients were selected. Trial and patient characteristics were extracted independently by two researchers. The combined effect on the composite primary endpoint was measured with a fixed-effect model. Potential publication bias was examined with a funnel plot.
Results: Five trials were included in the analysis comparing standard-dose statins with placebo with a total of 4 351 participants. Four trials were included for comparing standard-dose with intensive-dose statins, including 4 805 participants. Compared with placebo, standard-dose statin treatment resulted in a significant relative risk (RR) reduction of 15% in the occurrence of any major cardiovascular or cerebrovascular event (RR 0.85, 95% CI 0.79-0.91). Compared with standard-dose statin treatment, intensive-dose statin treatment resulted in an additional 9% relative risk reduction (RR 0.91, 95% CI 0.84-0.98).
Conclusion: Treatment with standard-dose statins to prevent cardiovascular or cerebrovascular events in diabetes patients with manifest cardiovascular disease results in an estimated 15% relative risk reduction and intensive-dose statin treatment adds 9%. If proven cost-effective, more intensive statin treatment should be recommended for diabetes patients at high cardiovascular risk.
|Number of pages||8|
|Publication status||Published - 5-Nov-2014|
- DENSITY-LIPOPROTEIN CHOLESTEROL, ACUTE CORONARY SYNDROMES, MYOCARDIAL-INFARCTION, LDL CHOLESTEROL, HEART-DISEASE, RANDOMIZED-TRIALS, CLINICAL-PRACTICE, 80 MG, SIMVASTATIN, MELLITUS